Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy.

The article, however, made a subtle but important mistake in characterizing the guidelines from the Department of Justice and the Federal Trade Commission published as a companion to the Medicare Shared Savings Program. The authors twice identify a “balance” between market power and integration efficiencies as the goal of the antitrust guidelines. The concept of balance misstates the vital role...

Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load.

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

BACKGROUND Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus constitute the backbone of lightened regimens. METHODS This was a monocentric, retrospective study. HIV-1-infected patients receiving dolutegravir as monotherapy (mDGV) or dual therapy (dDGV) were systematically identified. The primary outcome was the proportion of ...

Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy

BACKGROUND Good adherence to antiretroviral therapy (ART) is critical for successful HIV treatment. However, some patients remain virologically suppressed despite suboptimal adherence. We hypothesized that this could result from host genetic factors influencing drug levels. METHODS Eligible individuals were Caucasians treated with efavirenz (EFV) and/or boosted lopinavir (LPV/r) with self-rep...

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

BACKGROUND Little is known about the applicability of dual treatments based on integrase inhibitors. We explored the combination of lamivudine + dolutegravir as an option when switching from standard cART in virologically suppressed patients. METHODS In this prospective cohort we enrolled patients previously switched to 3TC + DTG who were 18 years or older, with no previous resistance mutatio...